

SCYNEXIS INC  
Form 4  
May 08, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
FCPR Biotechnology Fund

2. Issuer Name and Ticker or Trading Symbol  
SCYNEXIS INC [SCYX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

\_\_\_\_ Director  10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

57 RUE DE RICHELIEU

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(Street)

PARIS, IO 75002

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2014		X		5,251	A	\$ 0.2
Common Stock	05/07/2014		X		5,251	A	\$ 0.2
Common Stock	05/07/2014		X		25,998	A	\$ 0.2
Common Stock	05/07/2014		C		46,863	A	(1) 83,363
Common Stock	05/07/2014		C		88,796	A	(2) 172,159
	05/07/2014		C		42,336	A	(3) 214,495

Edgar Filing: SCYNEXIS INC - Form 4

Common Stock							
Common Stock	05/07/2014		C	30,582	A	(4)	245,077 D
Common Stock	05/07/2014		P	50,000	A	\$ 10	295,077 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrant (right to buy)	\$ 0.2	05/07/2014		X	5,251	12/07/2011	12/06/2016	Common Stock	5,251
Common Stock Warrant (right to buy)	\$ 0.2	05/07/2014		X	5,251	05/15/2012	05/14/2017	Common Stock	5,251
Common Stock Warrant (right to buy)	\$ 0.2	05/07/2014		X	25,998	12/11/2013	12/10/2018	Common Stock	25,998
Series B Preferred Stock	(1)	05/07/2014		C	166,482	(1)	(1)	Common Stock	46,863
Series C Preferred Stock	(2)	05/07/2014		C	313,996	(2)	(2)	Common Stock	88,796

Series D-1 Preferred Stock	<u>(3)</u>	05/07/2014	C	863,672	<u>(3)</u>	<u>(3)</u>	Common Stock	42,336
Series D-2 Preferred Stock	<u>(4)</u>	05/07/2014	C	623,880	<u>(4)</u>	<u>(4)</u>	Common Stock	30,582

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FCPR Biotechnology Fund 57 RUE DE RICHELIEU PARIS, IO 75002			X	

## Signatures

By: /s/ Jean-Yves Nothias,  
Director

05/08/2014

\_\_\_\_\_  
\*Signature of Reporting Person

\_\_\_\_\_  
Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-3.536 basis, and had no expiration date.
  - (2) Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-3.536 basis, and had no expiration date.
  - (3) Upon closing of the Issuer's initial public offering, each share of Series D-1 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.
  - (4) Upon closing of the Issuer's initial public offering, each share of Series D-2 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.